A61K 2039/55522
Cytokines
Official title: {Cytokines; Lymphokines; Interferons}
A61K2039/55522 (Cytokines) appears on 1,140 US grants and 1,916 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,140
- Published applications
- 1,916
- Assignees
- 728
- Inventors
- 2,635
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 5 | 0 |
| 1998 | 12 | 0 |
| 1999 | 21 | 0 |
| 2000 | 16 | 0 |
| 2001 | 16 | 16 |
| 2002 | 21 | 51 |
| 2003 | 12 | 59 |
| 2004 | 18 | 89 |
| 2005 | 15 | 59 |
| 2006 | 28 | 54 |
| 2007 | 27 | 68 |
| 2008 | 26 | 47 |
| 2009 | 25 | 60 |
| 2010 | 35 | 86 |
| 2011 | 34 | 67 |
| 2012 | 36 | 68 |
| 2013 | 36 | 48 |
| 2014 | 51 | 69 |
| 2015 | 43 | 63 |
| 2016 | 47 | 81 |
| 2017 | 47 | 77 |
| 2018 | 54 | 91 |
| 2019 | 63 | 100 |
| 2020 | 93 | 140 |
| 2021 | 109 | 128 |
| 2022 | 53 | 108 |
| 2023 | 54 | 91 |
| 2024 | 44 | 77 |
| 2025 | 44 | 71 |
| 2026 | 35 | 48 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compositions comprising non-immunogenic RNA encoding immunogenic epitopes and interferon alpha14 Jul 2026US 12,678,497 B2BioNTech SE
- Cancer vaccines targeting Survivin and uses thereof14 Jul 2026US 12,679,904 B2Inovio Pharmaceuticals, Inc.
- Treatment involving non-immunogenic rna for antigen vaccination8 Oct 2026US 2026/0306625 A1BioNTech SE
- Rna for preventing or treating tuberculosis24 Sep 2026US 2026/0284168 A1
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- Biodegradable scaffolds for enhancing vaccine efficacy24 Sep 2026US 2026/0284184 A1The Regents of the University of California
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines290US 6,218,371 B1University of Iowa Research Foundation · 2001
- Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling242US 5,811,097 AThe Regents of the University of California · 1998
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Composition and method for delivery of biologically-active factors209US 6,274,552 B1CytImmune Sciences, Inc. · 2001